LEHIGH VALLEY
- Type
- Teaching hospital
- Where
- Allentown, PA
- Medicare CCN
- 390133
- Received
- $2,932,857 in 621 records, 2019 ($416,029 general, $2,516,827 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: Lehigh Valley Corp. Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2019 | General payment | 398 | $416,029 |
| 2019 | Research payment | 223 | $2,516,827 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 223 | $2,516,827 |
| Space rental or facility fees (teaching hospital only) | 319 | $184,500 |
| Charitable Contribution | 5 | $146,741 |
| Gift | 28 | $39,314 |
| Grant | 4 | $20,155 |
| Education | 10 | $14,439 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 29 | $7,854 |
| Consulting Fee | 2 | $3,000 |
| Food and Beverage | 1 | $25 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2019-12-31 | LivaNova USA, Inc. | $8,839 | Gift | In-kind items and services | XTRA Autotransfusion System Device, Cardiology/Vascular Diseases | 2019 | |
| 2019-12-31 | AstraZeneca UK Limited | $1,062 | Research payment | In-kind items and services | EPANOVA Drug, Cardiovascular and Metabolism | A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs wi | 2019 |
| 2019-12-31 | Stryker Corporation | $484 | Gift | In-kind items and services | AXS UNIVERSAL Device, ASPIRATION | 2019 | |
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | $149 | Research payment | In-kind items and services | EPANOVA Drug, Cardiovascular and Metabolism | A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs wi | 2019 |
| 2019-12-30 | E.R. Squibb & Sons, L.L.C. | $3,500 | Research payment | Cash or cash equivalent | Ph III MIBC Nivo NKTR vs Nivo mono | 2019 | |
| 2019-12-26 | AstraZeneca Pharmaceuticals LP | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | BYDUREON Drug, Cardiovascular and Metabolism | 2019 | |
| 2019-12-23 | Lilly USA, LLC | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-12-23 | Merck Sharp & Dohme LLC | $250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2019 | |
| 2019-12-20 | Eisai Inc. | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Lenvima Drug, Oncology | 2019 | |
| 2019-12-20 | Novartis Pharmaceuticals Corporation | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | MEKINIST Drug, ONCOLOGY | 2019 | |
| 2019-12-19 | Sterilmed, Inc. | $559 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-12-19 | Stryker Corporation | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | TREVO Device, MICROCATHETERSTENTRIEVER | 2019 | |
| 2019-12-19 | Incyte Corporation | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | JAKAFI Drug, Hematology/Oncology | 2019 | |
| 2019-12-19 | Incyte Corporation | $250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | JAKAFI Drug, Hematology/Oncology | 2019 | |
| 2019-12-19 | Sterilmed, Inc. | $112 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-12-18 | Amgen Inc. | $250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | XGEVA Biological, Oncology | 2019 | |
| 2019-12-18 | Astellas Pharma US Inc | $250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | 2019 | |
| 2019-12-18 | TAIHO ONCOLOGY, INC. | $250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Lonsurf Drug, Oncology | 2019 | |
| 2019-12-17 | Medtronic, Inc. | $27,051 | Research payment | Cash or cash equivalent | Attain Device, Leads | PSR-CVG | 2019 |
| 2019-12-17 | Merck Sharp & Dohme LLC | $2,086 | Research payment | Cash or cash equivalent | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerabilit | 2019 |
| 2019-12-17 | Alexion Pharmaceuticals, Inc. | $1,200 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | SOLIRIS Drug, Immunology | 2019 | |
| 2019-12-17 | Amgen Inc. | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Kyprolis Biological, Oncology | 2019 | |
| 2019-12-17 | Alexion Pharmaceuticals, Inc. | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | SOLIRIS Drug, Immunology | 2019 | |
| 2019-12-16 | Medtronic Vascular, Inc. | $14,909 | Research payment | Cash or cash equivalent | Viva Device, Implantable Cardioverter Defibrillators (ICDs) | AdaptResponse | 2019 |
| 2019-12-16 | Boston Scientific Corporation | $1,560 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | APPRAISE ATP | 2019 |
| 2019-12-16 | Janssen Research & Development, LLC | $1,500 | Research payment | Cash or cash equivalent | OPSUMIT Drug, CARDIOVASCULAR DISORDERS | SERENADE - AC055G202 | 2019 |
| 2019-12-16 | Merck Sharp & Dohme LLC | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2019 | |
| 2019-12-13 | Amgen Inc. | $250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Kyprolis Biological, Oncology | 2019 | |
| 2019-12-12 | Medtronic USA, Inc. | $2,380 | Research payment | Cash or cash equivalent | SYNCHROMED Device, Drug Infusion Systems | Embrace TDD | 2019 |
| 2019-12-12 | CSL Behring | $1,639 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-12-12 | SEAGEN INC. | $250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ADCETRIS Biological, Oncology | 2019 | |
| 2019-12-10 | Medtronic USA, Inc. | $450 | Research payment | Cash or cash equivalent | SYNCHROMED Device, Drug Infusion Systems | Embrace TDD | 2019 |
| 2019-12-10 | GENZYME CORPORATION | $250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | CABLIVI Drug, RARE BLOOD DISORDERS | 2019 | |
| 2019-12-09 | Medtronic Vascular, Inc. | $1,500 | Research payment | Cash or cash equivalent | Arctic Front Device, Ablation | STOP AF First | 2019 |
| 2019-12-09 | Medtronic Vascular, Inc. | $450 | Research payment | Cash or cash equivalent | Arctic Front Device, Ablation | STOP AF First | 2019 |
| 2019-12-05 | Genentech, Inc. | $4,298 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | NEOADJUVANT NSCLC | 2019 |
| 2019-12-05 | PFIZER INC. | $260 | Research payment | Cash or cash equivalent | BAVENCIO Drug, ONCOLOGY | A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY CISPLATIN PLUS | 2019 |
| 2019-12-05 | GENZYME CORPORATION | $250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | JEVTANA Drug, ONCOLOGY | 2019 | |
| 2019-12-04 | E.R. Squibb & Sons, L.L.C. | $2,511 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III Adjuvant Melanoma Stage II B C Opdivo Mono | 2019 |
| 2019-12-04 | GENZYME CORPORATION | $250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ELITEK Drug, ONCOLOGY | 2019 | |
| 2019-12-03 | HOLOGIC INC | $3,655 | Grant | In-kind items and services | Securview Device, Breast and Skeletal Health | 2019 | |
| 2019-12-03 | Medtronic Vascular, Inc. | $793 | Research payment | Cash or cash equivalent | Reveal LINQ Device, Cardiac Diagnostics and Monitoring | Reveal LINQ Registry | 2019 |
| 2019-12-02 | Boston Scientific Corporation | $4,927 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | APPRAISE ATP | 2019 |
| 2019-12-02 | Boston Scientific Corporation | $390 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | PREEMPT HF | 2019 |
| 2019-12-02 | PFIZER INC. | $250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | 2019 | |
| 2019-11-25 | Medline Industries LP | $500 | Research payment | Cash or cash equivalent | MED-2018-DIV31-006 - Hyalomatrix | 2019 | |
| 2019-11-21 | Medtronic, Inc. | $31,534 | Research payment | Cash or cash equivalent | 2019 | ||
| 2019-11-21 | E.R. Squibb & Sons, L.L.C. | $21,750 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase IIA 2L Prostate Ipi Nivo Combo | 2019 |
| 2019-11-20 | E.R. Squibb & Sons, L.L.C. | $1,500 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Ph IIB NSCLC 3L squamous refractory | 2019 |
| 2019-11-19 | Sterilmed, Inc. | $436 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-11-19 | Sterilmed, Inc. | $67 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-11-18 | Boston Scientific Corporation | $1,500 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | PREEMPT HF | 2019 |
| 2019-11-18 | Insulet Corporation | $1,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2019 | |
| 2019-11-14 | Olympus Corporation | $10,000 | Research payment | Cash or cash equivalent | Olympus Duodenoscopes Device, GI & Respiratory Products | 2019 | |
| 2019-11-14 | GENZYME CORPORATION | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | LIBTAYO Drug, ONCOLOGY | 2019 | |
| 2019-11-14 | Abbott Laboratories | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Cardiovascular- Research only Device, Cardiac Arrhythmias and Heart Failure | 2019 | |
| 2019-11-14 | Novartis Pharmaceuticals Corporation | $250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | TASIGNA Drug, HEMATOLOGY | 2019 | |
| 2019-11-14 | AstraZeneca Pharmaceuticals LP | $250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | CALQUENCE Drug, Oncology | 2019 | |
| 2019-11-13 | E.R. Squibb & Sons, L.L.C. | $1,500 | Research payment | Cash or cash equivalent | SPRYCEL Drug, Oncology | Studying Interventions for Managing Patients With Chronic Myeloid Leukemia CML in Chronic Phase The 5-Year Prospective C | 2019 |
| 2019-11-13 | PFIZER INC. | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | 2019 | |
| 2019-11-12 | Pharmacyclics LLC, an AbbVie Company | $250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Imbruvica Drug, Oncology | 2019 | |
| 2019-11-11 | Mallinckrodt Enterprises LLC | $35,306 | Research payment | Cash or cash equivalent | A PHASE 2B3 PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, SHAM-CONTROLLED TRIAL OF VTS-270 2-HYDROXYPROPYL--CYCLODEXTRIN IN SUB | 2019 | |
| 2019-11-11 | Mallinckrodt Enterprises LLC | $1,500 | Research payment | Cash or cash equivalent | A PHASE 2B3 PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, SHAM-CONTROLLED TRIAL OF VTS-270 2-HYDROXYPROPYL--CYCLODEXTRIN IN SUB | 2019 | |
| 2019-11-11 | Mallinckrodt Enterprises LLC | $280 | Research payment | Cash or cash equivalent | A PHASE 2B3 PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, SHAM-CONTROLLED TRIAL OF VTS-270 2-HYDROXYPROPYL--CYCLODEXTRIN IN SUB | 2019 | |
| 2019-11-11 | Mallinckrodt Enterprises LLC | $215 | Research payment | Cash or cash equivalent | A PHASE 2B3 PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, SHAM-CONTROLLED TRIAL OF VTS-270 2-HYDROXYPROPYL--CYCLODEXTRIN IN SUB | 2019 | |
| 2019-11-11 | Mallinckrodt Enterprises LLC | $215 | Research payment | Cash or cash equivalent | A PHASE 2B3 PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, SHAM-CONTROLLED TRIAL OF VTS-270 2-HYDROXYPROPYL--CYCLODEXTRIN IN SUB | 2019 | |
| 2019-11-09 | SANOFI-AVENTIS U.S. LLC | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | TOUJEO Drug, DIABETES | 2019 | |
| 2019-11-08 | Merck Sharp & Dohme LLC | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2019 | |
| 2019-11-07 | CSL Behring | $8,840 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-11-07 | CSL Behring | $780 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-11-05 | Eisai Inc. | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Lenvima Drug, Oncology | 2019 | |
| 2019-11-05 | Merck Sharp & Dohme LLC | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2019 | |
| 2019-11-04 | Boston Scientific Corporation | $1,102 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ASAP TOO | 2019 |
| 2019-11-04 | Merck Sharp & Dohme LLC | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2019 | |
| 2019-11-04 | Merck Sharp & Dohme LLC | $250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2019 | |
| 2019-10-31 | Bayer Healthcare Pharmaceuticals Inc. | $250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Nexavar Drug, Oncology | 2019 | |
| 2019-10-30 | Genentech, Inc. | $16,490 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | NEOADJUVANT NSCLC | 2019 |
| 2019-10-30 | Medtronic Vascular, Inc. | $15,500 | Research payment | Cash or cash equivalent | ECG Belt | 2019 | |
| 2019-10-30 | Abbott Laboratories | $2,023 | Research payment | Cash or cash equivalent | Optisure Lead Device, Cardiac Arrhythmias and Heart Failure | Optisure Lead Post Approval Study | 2019 |
| 2019-10-30 | GRT US Holding, Inc. | $1,500 | Research payment | Cash or cash equivalent | Neridronic acid Drug | KF7013-04 | 2019 |
| 2019-10-30 | Merck Sharp & Dohme LLC | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2019 | |
| 2019-10-28 | Novartis Pharmaceuticals Corporation | $250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | KISQALI Drug, ONCOLOGY | 2019 | |
| 2019-10-27 | AstraZeneca Pharmaceuticals LP | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | LYNPARZA Drug, Oncology | 2019 | |
| 2019-10-25 | Amgen Inc. | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Kyprolis Biological, Oncology | 2019 | |
| 2019-10-25 | Amgen Inc. | $250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Kyprolis Biological, Oncology | 2019 | |
| 2019-10-25 | Eisai Inc. | $250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Halaven Drug, Oncology | 2019 | |
| 2019-10-24 | Medtronic, Inc. | $65,021 | Research payment | Cash or cash equivalent | 2019 | ||
| 2019-10-24 | Medtronic Vascular, Inc. | $591 | Research payment | Cash or cash equivalent | Reveal LINQ Device, Cardiac Diagnostics and Monitoring | Reveal LINQ Registry | 2019 |
| 2019-10-24 | Ipsen Biopharmaceuticals, Inc | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | SOMATULINE DEPOT Drug, Oncology/Endocrinology | 2019 | |
| 2019-10-24 | Ipsen Biopharmaceuticals, Inc | $250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | SOMATULINE DEPOT Drug, Oncology/Endocrinology | 2019 | |
| 2019-10-23 | Sterilmed, Inc. | $469 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-10-23 | Sterilmed, Inc. | $161 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-10-22 | Bayer Healthcare Pharmaceuticals Inc. | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Nexavar Drug, Oncology | 2019 | |
| 2019-10-21 | Medtronic Vascular, Inc. | $4,615 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2019 |
| 2019-10-21 | Medtronic Vascular, Inc. | $4,615 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2019 |
| 2019-10-18 | AstraZeneca Pharmaceuticals LP | $943 | Research payment | Cash or cash equivalent | EPANOVA Drug, Cardiovascular and Metabolism | A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs wi | 2019 |
| 2019-10-11 | GENZYME CORPORATION | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | JEVTANA Drug, ONCOLOGY | 2019 | |
| 2019-10-10 | SANOFI PASTEUR INC. | $66,815 | Research payment | Cash or cash equivalent | YELLOW FEVER Drug | STA00011 Stamaril Yellow Fever | 2019 |
| 2019-10-09 | Boston Scientific Corporation | $1,500 | Grant | Cash or cash equivalent | GENERAL - ONCOLOGY Device, GENERAL | 2019 | |
| 2019-10-08 | KARL STORZ Endoscopy-America | $510 | Gift | In-kind items and services | TELESCOPE,HOPKINS II,AUTOCLAV, Device, UROLOGY | 2019 | |
| 2019-10-08 | Astellas Pharma US Inc | $250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | 2019 | |
| 2019-10-07 | Varian Medical Systems, Inc. | $1,500 | Consulting Fee | Cash or cash equivalent | TrueBeam Device, Devices | 2019 | |
| 2019-10-05 | COLOPLAST CORP | $750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-10-03 | Exelixis Inc. | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Cabometyx Drug, Oncology | 2019 | |
| 2019-10-03 | GE HEALTHCARE | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Device, ULTRASOUND | 2019 | |
| 2019-10-03 | Incyte Corporation | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | JAKAFI Drug, Hematology/Oncology | 2019 | |
| 2019-10-03 | E.R. Squibb & Sons, L.L.C. | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ELIQUIS Drug, Cardiovascular | 2019 | |
| 2019-10-03 | Ipsen Biopharmaceuticals, Inc | $250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | SOMATULINE DEPOT Drug, Oncology/Endocrinology | 2019 | |
| 2019-10-03 | Ipsen Biopharmaceuticals, Inc | $250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | SOMATULINE DEPOT Drug, Oncology/Endocrinology | 2019 | |
| 2019-10-02 | Medtronic Vascular, Inc. | $3,090 | Research payment | Cash or cash equivalent | Arctic Front Device, Ablation | STOP AF First | 2019 |
| 2019-10-02 | Pharmacyclics LLC, an AbbVie Company | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Imbruvica Drug, Oncology | 2019 | |
| 2019-10-02 | ABBVIE INC. | $250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Venclexta Drug, Virology | 2019 | |
| 2019-10-02 | Pharmacyclics LLC, an AbbVie Company | $250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Imbruvica Drug, Oncology | 2019 | |
| 2019-10-01 | AstraZeneca Pharmaceuticals LP | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | BYDUREON Drug, Cardiovascular and Metabolism | 2019 | |
| 2019-10-01 | PFIZER INC. | $250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | 2019 | |
| 2019-09-30 | KARL STORZ Endoscopy-America | $5,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | CYSTOSCOPE-URETHROSCOPE SHEATH ONLY,17FR Device, UROLOGY | 2019 | |
| 2019-09-30 | Medtronic Vascular, Inc. | $797 | Research payment | In-kind items and services | ECG Belt | 2019 | |
| 2019-09-30 | Amgen Inc. | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Blincyto Biological, Oncology | 2019 | |
| 2019-09-29 | Merck Sharp & Dohme LLC | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2019 | |
| 2019-09-27 | Allergan, Inc. | $1,500 | Education | Cash or cash equivalent | 2019 | ||
| 2019-09-27 | E.R. Squibb & Sons, L.L.C. | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | OPDIVO Biological, Oncology | 2019 | |
| 2019-09-27 | GENZYME CORPORATION | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | LIBTAYO Drug, ONCOLOGY | 2019 | |
| 2019-09-27 | E.R. Squibb & Sons, L.L.C. | $250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | OPDIVO Biological, Oncology | 2019 | |
| 2019-09-26 | Olympus Corporation of the Americas | $10,000 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-09-26 | Bayer Healthcare Pharmaceuticals Inc. | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Xofigo Drug, Oncology | 2019 | |
| 2019-09-24 | CSL Behring | $1,500 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-09-24 | ABBVIE INC. | $1,500 | Research payment | Cash or cash equivalent | M14-011 | 2019 | |
| 2019-09-24 | Pharmacyclics LLC, an AbbVie Company | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Imbruvica Drug, Oncology | 2019 | |
| 2019-09-23 | Lilly USA, LLC | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-09-23 | Lilly USA, LLC | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-09-23 | Lilly USA, LLC | $250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-09-20 | Medtronic, Inc. | $21,407 | Research payment | Cash or cash equivalent | Attain Device, Leads | PSR-CVG | 2019 |
| 2019-09-20 | W. L. Gore & Associates, Inc. | $16,000 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | GORE CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients with P | 2019 |
| 2019-09-20 | GENZYME CORPORATION | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ELITEK Drug, ONCOLOGY | 2019 | |
| 2019-09-20 | PFIZER INC. | $250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | INLYTA Drug, ONCOLOGY | 2019 | |
| 2019-09-19 | Merck Sharp & Dohme LLC | $1,500 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Ax | 2019 |
| 2019-09-19 | Merck Sharp & Dohme LLC | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2019 | |
| 2019-09-19 | PFIZER INC. | $250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | 2019 | |
| 2019-09-18 | KCI USA, Inc. | $800 | Education | Cash or cash equivalent | PREVENA Device, NON-COVERED | 2019 | |
| 2019-09-17 | Medtronic Vascular, Inc. | $12,827 | Research payment | Cash or cash equivalent | Viva Device, Implantable Cardioverter Defibrillators (ICDs) | AdaptResponse | 2019 |
| 2019-09-17 | PFIZER INC. | $5,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | 2019 | |
| 2019-09-17 | Becton, Dickinson and Company | $887 | Education | In-kind items and services | 2019 | ||
| 2019-09-16 | Boston Scientific Corporation | $5,168 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | APPRAISE ATP | 2019 |
| 2019-09-16 | Eisai Inc. | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Lenvima Drug, Oncology | 2019 | |
| 2019-09-13 | Boston Scientific Corporation | $693 | Research payment | Cash or cash equivalent | ACUITY Device, TACHY | NAVIGATE X4 STUDY | 2019 |
| 2019-09-12 | Novocure Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Oncology Device, Optune | 2019 | |
| 2019-09-11 | Merck Sharp & Dohme LLC | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2019 | |
| 2019-09-11 | Merck Sharp & Dohme LLC | $250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2019 | |
| 2019-09-10 | Merck Sharp & Dohme LLC | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2019 | |
| 2019-09-10 | PFIZER INC. | $250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | 2019 | |
| 2019-09-10 | ABBVIE INC. | $250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Venclexta Drug, Virology | 2019 | |
| 2019-09-10 | Merck Sharp & Dohme LLC | $65 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab MK-3475 plus Chemotherapy vs Placebo plus Chemotherapy for | 2019 |
| 2019-09-10 | Merck Sharp & Dohme LLC | $32 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab MK-3475 plus Chemotherapy vs Placebo plus Chemotherapy for | 2019 |
| 2019-09-10 | Merck Sharp & Dohme LLC | $27 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab MK-3475 plus Chemotherapy vs Placebo plus Chemotherapy for | 2019 |
| 2019-09-10 | Merck Sharp & Dohme LLC | $13 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab MK-3475 plus Chemotherapy vs Placebo plus Chemotherapy for | 2019 |
| 2019-09-10 | Merck Sharp & Dohme LLC | $7 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab MK-3475 plus Chemotherapy vs Placebo plus Chemotherapy for | 2019 |
| 2019-09-10 | Merck Sharp & Dohme LLC | $6 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab MK-3475 plus Chemotherapy vs Placebo plus Chemotherapy for | 2019 |
| 2019-09-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-09-06 | Medtronic, Inc. | $37,226 | Research payment | Cash or cash equivalent | 2019 | ||
| 2019-09-06 | Alexion Pharmaceuticals, Inc. | $250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | SOLIRIS Drug, Immunology | 2019 | |
| 2019-09-06 | Aesculap, Inc. | $246 | Gift | Cash or cash equivalent | 2019 | ||
| 2019-09-05 | Abbott Laboratories | $1,500 | Research payment | Cash or cash equivalent | Optisure Lead Device, Cardiac Arrhythmias and Heart Failure | Optisure Lead Post Approval Study | 2019 |
| 2019-09-04 | Bayer Healthcare Pharmaceuticals Inc. | $5,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Xofigo Drug, Oncology | 2019 | |
| 2019-09-04 | STERIS CORPORATION | $800 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Exacto Cold Snare Device, 78 Gastroenterology | 2019 | |
| 2019-09-04 | PFIZER INC. | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | 2019 | |
| 2019-09-04 | Sterilmed, Inc. | $364 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-09-04 | Sterilmed, Inc. | $41 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-09-03 | Boston Scientific Corporation | $10,664 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | PREEMPT HF | 2019 |
| 2019-09-03 | Medtronic USA, Inc. | $4,771 | Research payment | Cash or cash equivalent | RESTORE Device, Spinal Cord Neurostimulation | Vectors PM | 2019 |
| 2019-09-03 | Medline Industries LP | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-09-03 | Medline Industries LP | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-09-03 | Medline Industries LP | $400 | Research payment | Cash or cash equivalent | 11th Annual Flemming Infection Prevention and Infection Control | 2019 | |
| 2019-09-03 | Medline Industries LP | $400 | Research payment | Cash or cash equivalent | 11th Annual Flemming Infection Prevention and Infection Control | 2019 | |
| 2019-09-03 | GENZYME CORPORATION | $250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ELITEK Drug, ONCOLOGY | 2019 | |
| 2019-09-03 | Bayer Healthcare Pharmaceuticals Inc. | $250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Xofigo Drug, Oncology | 2019 | |
| 2019-08-30 | E.R. Squibb & Sons, L.L.C. | $1,500 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III MEL 1L, PD-1 vs Ipi vs. PD-1 Ipi | 2019 |
| 2019-08-29 | Merck Sharp & Dohme LLC | $525 | Research payment | Cash or cash equivalent | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerabilit | 2019 |
| 2019-08-28 | Blue Earth Diagnostics | $750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Axumin Drug, Diagnostic Imaging | 2019 | |
| 2019-08-27 | PFIZER INC. | $5,952 | Research payment | Cash or cash equivalent | BAVENCIO Drug, ONCOLOGY | A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY CISPLATIN PLUS | 2019 |
| 2019-08-27 | Exelixis Inc. | $4,500 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Randomized, Double-blinded Phase III Study of Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumor | 2019 |
| 2019-08-27 | Exelixis Inc. | $4,500 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Randomized, Double-blinded Phase III Study of Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumor | 2019 |
| 2019-08-27 | Exelixis Inc. | $4,500 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Randomized, Double-blinded Phase III Study of Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumor | 2019 |
| 2019-08-27 | Merck Sharp & Dohme LLC | $1,760 | Research payment | Cash or cash equivalent | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerabilit | 2019 |
| 2019-08-27 | Merck Sharp & Dohme LLC | $1,500 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase II Study of Pembrolizumab Monotherapy in Third-line Previously Treated Subjects with Advanced,Metastatic Adenoca | 2019 |
| 2019-08-27 | Exelixis Inc. | $122 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Randomized, Double-blinded Phase III Study of Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumor | 2019 |
| 2019-08-27 | Exelixis Inc. | $122 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Randomized, Double-blinded Phase III Study of Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumor | 2019 |
| 2019-08-27 | Exelixis Inc. | $122 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Randomized, Double-blinded Phase III Study of Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumor | 2019 |
| 2019-08-27 | Exelixis Inc. | $25 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Randomized, Double-blinded Phase III Study of Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumor | 2019 |
| 2019-08-27 | Exelixis Inc. | $25 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Randomized, Double-blinded Phase III Study of Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumor | 2019 |
| 2019-08-27 | Exelixis Inc. | $25 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Randomized, Double-blinded Phase III Study of Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumor | 2019 |
| 2019-08-26 | Amgen Inc. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Kyprolis Biological, Oncology | 2019 | |
| 2019-08-23 | Mallinckrodt Enterprises LLC | $46,443 | Research payment | Cash or cash equivalent | A PHASE 2B3 PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, SHAM-CONTROLLED TRIAL OF VTS-270 2-HYDROXYPROPYL--CYCLODEXTRIN IN SUB | 2019 | |
| 2019-08-23 | E.R. Squibb & Sons, L.L.C. | $5,167 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III Adjuvant Melanoma Monotherapy | 2019 |
| 2019-08-23 | Medtronic Vascular, Inc. | $3,124 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2019 |
| 2019-08-23 | Medtronic Vascular, Inc. | $3,124 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2019 |
| 2019-08-23 | Mallinckrodt Enterprises LLC | $1,785 | Research payment | Cash or cash equivalent | A PHASE 2B3 PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, SHAM-CONTROLLED TRIAL OF VTS-270 2-HYDROXYPROPYL--CYCLODEXTRIN IN SUB | 2019 | |
| 2019-08-23 | Astellas Pharma US Inc | $1,600 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | MYRBETRIQ Drug, UROLOGY | 2019 | |
| 2019-08-23 | Alexion Pharmaceuticals, Inc. | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | SOLIRIS Drug, Immunology | 2019 | |
| 2019-08-23 | Merck Sharp & Dohme LLC | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2019 | |
| 2019-08-23 | GENZYME CORPORATION | $250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | CABLIVI Drug, RARE BLOOD DISORDERS | 2019 |
The latest 200 records of 621.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
In Pennsylvania; placed by its state only.
| Measure | State Pennsylvania |
|---|---|
| Population B01003 | 13,018,639 |
| Population, 2020 census P1 | 13,002,700 |
| Median age B01002 | 40.9 |
| Under 18 B01001 | 20.4% |
| 65 and over B01001 | 19.5% |
| Households B11001 | 5,274,853 |
| Foreign born B05002 | 7.7% |
| Median household income B19013 | $77,971 |
| Median family income B19113 | $100,262 |
| Per capita income B19301 | $44,355 |
| Poverty rate B17001 | 11.7% |
| Unemployment rate B23025 | 5.3% |
| Civilian labor force B23025 | 6,684,175 |
| Mean commute (minutes) B08013 | 26.3 |
| Bachelor's degree or higher B15003 | 35.2% |
| Housing units B25001 | 5,806,452 |
| Owner-occupied B25003 | 69.3% |
| Renters B25003 | 30.7% |
| Median home value B25077 | $254,500 |
| Median gross rent B25064 | $1,209 |
| White, not Hispanic B03002 | 73.0% |
| Black B03002 | 10.3% |
| Hispanic or Latino B03002 | 8.7% |
| Asian B03002 | 3.8% |
| American Indian and Alaska Native B03002 | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Pennsylvania.
Comments